

## Malignant Hematology Areas of Interest

### (Investigator Initiated Studies and Research Collaborations)

#### **REGN1979 (CD20xCD3) odronextamab**

##### **Non-interventional proposals:**

- Predictors of response and/or (primary or acquired) resistance to Odronextamab in the treatment of b-NHL, including Investigating immune correlates of response to CD20xCD3 bispecific antibodies in B-NHL

##### **Interventional proposals:**

- Novel treatment combinations, including combinations with novel agents targeting non-redundant pathways, in all lines of therapy for the treatment of b-NHL.
- Sequencing or optimization of treatment regimen (e.g., new outpatient administration/monitoring protocols)
- Investigating Odronextamab in hard-to-treat, medically unaddressed, and rare populations with B-Cell malignancies in high unmet medical needs for treatment.

(6.0, Aug2025)

#### **REGN5458 (BCMA x CD3 bispecific antibody) linvoseltamab**

##### **Clinical Interventional proposals:**

- Multiple Myeloma
  - Novel treatment combinations
  - Unique sequencing strategies (e.g. optimization of BCMA retreatment, post GPRc5D bsAb)
  - Optimization of treatment administration (e.g. outpatient administration/monitoring, alternative dosing frequency and fixed duration, retreatment prior to progression)
  - Characterization and management of adverse events
  - Exploration in special patient subpopulations of high unmet need
  - Elucidation of resistance or relapse mechanisms
- Other plasma cell dyscrasias
- Non-plasma cell dyscrasia BCMA targetable hematologic malignancies

(v5.0, Oct2024)

***Regeneron is currently accepting proposals for Investigator Initiated Studies and Research Collaborations for Malignant Hematology Products in North America, United Kingdom (UK) and the European Union (EU).***